Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

PHASE4CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

July 4, 2017

Primary Completion Date

August 26, 2019

Study Completion Date

December 27, 2019

Conditions
Coronary Artery DiseaseSTEMI - ST Elevation Myocardial Infarction
Interventions
DRUG

Cangrelor

Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).

DRUG

Tirofiban

Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old) .

DRUG

Prasugrel

In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).

Trial Locations (3)

3010

Bern University Hospital, Bern

44124

University of Ferrara, Ferrara

80131

University of Naples Federico II, Naples

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT02978040 - Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI. | Biotech Hunter | Biotech Hunter